OPTIRAY 160 Drug Patent Profile

When do Optiray 160 patents expire, and what generic alternatives are available?

Optiray 160 is a drug marketed by Liebel-flarsheim and is included in one NDA.

The generic ingredient in OPTIRAY 160 is ioversol. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ioversol profile page.

Summary for OPTIRAY 160

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	73
Clinical Trials:	3
Patent Applications:	1,980
DailyMed Link:	OPTIRAY 160 at DailyMed

Recent Clinical Trials for OPTIRAY 160

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Duke Clinical Research Institute	Phase 4
GE Healthcare	Phase 4
Bayer	Phase 4

See all OPTIRAY 160 clinical trials

Pharmacology for OPTIRAY 160

Drug Class	Radiographic Contrast Agent
Mechanism of Action	X-Ray Contrast Activity

US Patents and Regulatory Information for OPTIRAY 160

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Liebel-flarsheim	OPTIRAY 160	ioversol	INJECTABLE;INJECTION	019710-003	Dec 30, 1988		DISCN	No	No

Expired US Patents for OPTIRAY 160

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Liebel-flarsheim	OPTIRAY 160	ioversol	INJECTABLE;INJECTION	019710-003	Dec 30, 1988	4,396,598

International Patents for OPTIRAY 160

See the table below for patents covering OPTIRAY 160 around the world.

Country	Patent Number	Title	Estimated Expiration
Germany	3362967
European Patent Office	0083964	COMPOUNDS SUITABLE FOR X-RAY VISUALISATION METHODS
Australia	552188
Japan	H0224252
Netherlands	930067
Canada	1198739	DERIVES DE 2,4,6-TRIIODOISOPHTALAMIDE (2,4,6-TRIIODOISOPHTHALAMIDE DERIVATIVE)
Japan	S58131970	COMPOUND

Supplementary Protection Certificates for OPTIRAY 160

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0083964	SPC/GB93/089	United Kingdom		SPC/GB93/089: 20041015
0083964	93C0142	Belgium		PRODUCT NAME: IOVERSOL; NAT. REGISTRATION NO/DATE: 74 IS 56 F12/19910521; FIRST REGISTRATION: NL RVG 13345 19891016

OPTIRAY 160 Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for OPTIRAY 160 (Ioversol 34% Injectable Solution)

Introduction

OPTIRAY 160, also known as Ioversol 34% Injectable Solution, is a non-ionic, low-osmolar contrast agent widely used in medical imaging procedures such as X-rays, CT scans, and other radiological examinations. This article delves into the market dynamics and financial trajectory of OPTIRAY 160, highlighting key factors influencing its growth and performance.

Market Segmentation

The global Ioversol market, including OPTIRAY 160, is segmented based on type, application, and geography.

By Type

• Ioversol 34% Injectable Solution (Optiray 160)
• Ioversol 51% Injectable Solution (Optiray 240)
• Ioversol 64% Injectable Solution (Optiray 300)
• Ioversol 68% Injectable Solution (Optiray 320)
• Ioversol 74% Injectable Solution (Optiray 350)[1][4][5].

By Application

• X-ray
• CT Scan
• Brain Disorders
• Blood Vessel Disorders
• Heart Disorders
• Others[1][4][5].

By Geography

• North America
• Europe
• Asia-Pacific
• LAMEA (Latin America, Middle East, and Africa)[1][4][5].

Market Drivers

Several factors drive the growth of the OPTIRAY 160 market:

Increase in Accidents and Prevalence of Diseases

The rise in the number of accidents and the increasing prevalence of bone-related diseases and kidney problems are significant drivers. These conditions often require diagnostic imaging, thereby increasing the demand for contrast agents like OPTIRAY 160[4].

Growth in Geriatric Population

The growing geriatric population is associated with an increase in orthopedic and cardiovascular disorders, which in turn fuels the demand for X-ray and other diagnostic imaging procedures[4].

Advancements in Diagnostic Technologies

Advancements in X-ray, CT scan, and other radiological and diagnostic examinations also contribute to the market growth. These advancements make procedures more accurate and efficient, increasing the use of contrast agents[4].

Market Restraints

Despite the growth drivers, there are several restraints to consider:

Adverse Reactions

Overdose or allergic reactions to ioversol can lead to serious side effects such as breathing problems, swelling of the face, lips, tongue, or throat, and dehydration. These risks can limit the market growth[4].

Market Size and Growth Rate

The global Ioversol market, including OPTIRAY 160, is witnessing significant growth.

Current Market Size

In 2023, the Ioversol 34% Injectable Solution (Optiray 160) segment accounted for a noticeable share of the global Ioversol market[1].

Forecasted Growth

The market is projected to experience significant growth in the near future, with the X-ray segment expected to expand at a significant CAGR throughout the forecast period[1][5].

Financial Performance of Key Players

Companies like Liebel Flarsheim Company LLC, Guerbet, Jiangsu Hengrui Medicine Co, and Mallinckrodt Pharmaceuticals are key players in the Ioversol market.

Mallinckrodt Pharmaceuticals

Mallinckrodt Pharmaceuticals, a significant player in the global medical imaging segment, reported notable financial performance in recent years. For example, in the fiscal second quarter of 2014, the company's Global Medical Imaging segment saw net sales and operating income that reflected the segment's importance to the company's overall financial health[2].

Competitive Landscape

The competitive landscape of the Ioversol market is characterized by several key companies focusing on strategy and product portfolio expansion.

Key Companies

• Liebel Flarsheim Company LLC
• Guerbet
• Jiangsu Hengrui Medicine Co
• Mallinckrodt Pharmaceuticals
• Ultraject
• China Resources Pharmaceutical (Shanghai) Co
• HB Ocean
• Novalek Pharmaceuticals Pvt. Ltd
• Stellence Pharmscience Pvt. Ltd
• A.S. Joshi & Company[1][4][5].

Geographical Analysis

The global Ioversol market is geographically segmented into North America, Europe, Asia-Pacific, and LAMEA.

Dominant Regions

North America and Europe are expected to be significant regions for the Ioversol market, driven by advanced healthcare infrastructure and high spending on diagnostic procedures. However, the Asia-Pacific region is also anticipated to show substantial growth due to increasing healthcare expenditure and a growing geriatric population[1][4][5].

Opportunities and Challenges

Opportunities

• Increased Healthcare Spending: Rising healthcare expenditure globally is expected to provide new opportunities for the market players.
• Advancements in Diagnostic Technologies: Continuous advancements in X-ray, CT scan, and other radiological and diagnostic examinations will drive the demand for contrast agents like OPTIRAY 160[4].

Challenges

• Regulatory Hurdles: Strict regulatory requirements and the need for compliance can pose challenges for market growth.
• Side Effects and Safety Concerns: The potential for adverse reactions and safety concerns associated with ioversol use can limit market expansion[4].

Key Takeaways

• Market Growth: The Ioversol market, including OPTIRAY 160, is expected to experience significant growth driven by increasing demand for diagnostic imaging procedures.
• Segment Dominance: The X-ray segment is anticipated to expand at a significant CAGR throughout the forecast period.
• Geographical Expansion: North America and Europe are dominant regions, but the Asia-Pacific region is expected to show substantial growth.
• Competitive Landscape: Key companies are focusing on strategy and product portfolio expansion to strengthen their market position.
• Challenges and Opportunities: While regulatory hurdles and safety concerns are challenges, advancements in diagnostic technologies and increased healthcare spending present opportunities.

FAQs

What are the primary applications of OPTIRAY 160?

OPTIRAY 160 is primarily used in X-ray, CT scan, brain disorders, blood vessel disorders, heart disorders, and other radiological examinations[1][4][5].

Which segment of the Ioversol market is expected to grow significantly?

The X-ray segment is expected to expand at a significant CAGR throughout the forecast period[1][5].

What are the key drivers of the Ioversol market?

Key drivers include the rise in accidents, prevalence of bone-related diseases and kidney problems, growth in the geriatric population, and advancements in diagnostic technologies[4].

What are the potential side effects of using ioversol?

Potential side effects include allergic reactions, breathing problems, swelling of the face, lips, tongue, or throat, and dehydration[4].

Which companies are major players in the Ioversol market?

Major players include Liebel Flarsheim Company LLC, Guerbet, Jiangsu Hengrui Medicine Co, Mallinckrodt Pharmaceuticals, and others[1][4][5].

Sources

1. Global Ioversol Market Report 2024 Edition - Cognitivemarketresearch.com
2. Mallinckrodt plc Reports Fiscal 2014 Second Quarter Financial Results - Mallinckrodt.com
3. INFORMATION STATEMENT Mallinckrodt plc - Mallinckrodt.gcs-web.com
4. Global Ioversol Market - Alliedmarketresearch.com
5. Ioversol-Marktgrößenprognose - Marketresearchintellect.com